Lupus nephritis. Remissions and relapses. Long-term follow up of 84 patients
Abstract
Introduction: Nephritis is the most common of all serious manifestations of SLE. The proliferative forms require immunosuppressive treatment, but responses are not consistent and exacerbations are frequent during or after the treatment has been completed. Methods: We retrospectively analyzed the evolution of a cohort of 84 patients with proliferative lupus nephritis with immunosuppressive treatment, in a long-term (up to 203 months) follow up. Were taken as basal: sex, age, latency between onset and diagnosis of SLE nephritis, serum complement, plasmatic creatinine and proteinuria. We evaluated: initial response to therapy, occurrence of relapse or recurrence and score at the end of the observation period. Results: Remission of initial nephritis was seen in 73% of the cases, although at the end of monitoring only 54% of patients were in remission. 45 patients had one episode of nephritis, 32 patients had two, and 7 patients had three. Most of the remissions took place during the maintenance period. Complete remission had better evolution than partial remission. High serum creatinine levels and proteinuria at baseline were indicators of bad prognosis. Oral Azathioprine was more effective than quarterly IV Cylophosphamide as maintenance therapy, despite of a high incidence of relapses. Mycophenolate was not more effective than Cyclophosphamide/azathioprine for the treatment of relapses or recurrences. Conclusions: Our results are similar to the literature. Extended follow up enables the evaluation of the long term result of the initial symptoms, any possible future outbreaks, the effectiveness of the treatment and its evolution after its interruption.
References
Mavragani CP, Moutsopoulos HM. Lupus nephritis: current issues. Ann Rheum Dis. 2003;62:795-98.
Pons-Estel BA, Catoggio LJ, Cardiel MH, et al. The GLADEL multinational Latin American prospective inception cohort of 1, 214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among “Hispanics". Medicine (Baltimore). 2004;83:1–17.
Weening JJ, D’Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65:521-30.
Hahn Bh, Mc Mahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012;64(6):797-808.
Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71:1771–82.
Ruiz-Irastorza G, Espinosa G, Frutos MA, et al. Diagnóstico y tratamiento de la nefritis lúpica. Nefrología. 2012;32(Suppl. 1):1-35.
Van Tellingen A, Voskuyl AE, Vervloet MG, et al. Dutch guidelines for diagnosis and therapy of proliferative lupus nephritis. Neth J Med. 2012;70(4):199-207.
Kidney Disease Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl. 2012;2:139–274.
Illei GG, Takada K, Parkin D, et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy. Arthritis Rheum. 2002;46:995–1002.
Moroni G, Quaglini S, Gallelli B, et al. The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrol Dial Transplant. 2007;22:2531–39.
Ponticelli C, Glassock R, Moroni G. Induction and maintenance therapy in proliferative lupus nephritis. J Nephrol. 2010;23(1):9-16.
Tesar V, Hruskova Z. Treatment of proliferative lupus nephritis: a slowly changing landscape. Nat Rev Nephrol. 2011;7:96-109.
Petri M, Perez-Gutthann S, Longenecker JC, et al. Morbidity of systemic lupus erythematosus: role of race and socioeconomic status. Am J Med. 1991;91:345–53.
Bastian HM, Roseman JM, McGwin G Jr, et al. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus. 2002;11(3):152-60.
Lee SJ, Silverman E, Bargman JM. The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nat Rev Nephrol. 2011;7:718-29.
Wallace DJ, Gudsoorkar VS, Weisman MH, et al. New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat Rev Rheum. 2012;8:522-33.
Fischer-Betz R, Chehab G, Sander O, et al. Renal outcome in patients with lupus nephritis using a steroid-free regimen of monthly intravenous cyclophosphamide: a prospective observational study. J Rheumatol. 2012;39(11):2111-7.
Catapano F, Chaudhry AN, Jones RB, et al. Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. Nephrol Dial Transplant. 2010;25:3586–92.
Ripoll E, Merino A, Grinyó JM, et al. New Approaches for the treatment of lupus nephritis in the 21st century. Immunotherapy. 2013;5:1089-101.
Houssiau FA, Vasconcelos C, D’Cruz D, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum. 2004;50(12):3934-40.
Stephen M. Korbet SM, Lewis EJ. Severe lupus nephritis: the predictive value of a≥50% reduction in proteinuria at 6 months. Nephrol Dial Transplant. 2013;28:2313–18.
Chen YE, Korbet SM, Katz RS, et al. Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol. 2008;3:46–53.
Appel GB, Contreras G, Dooley MA, et al. Mycophenolate Mofetil versus Cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20:1103–12.
Dooley MA, Jayne D, Ginzler EM, Isenberg D et al. Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis. N Engl J Med. 2011;365:1886-95.
Houssiau FA, D’ Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for longterm immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis. 2010;69:2083–89.
Chan TM, Tse KC, Tang CS, Mok MY et al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol. 2005;16:1076-84.
Houssiau FA, Vasconcelos C, D’Cruz D, et al. Immunosuppressive therapy in lupus nephritis. Arthritis Rheum. 2002;46:2121–31.
Grootscholten C, Ligtenberg G, Hagen EC, et al. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int. 2006;70:732–42.
Grootscholten C, Berden JHM. Discontinuation of immunosuppression in proliferative lupus nephritis: is it possible? Nephrol Dial Transplant. 2006;21:1465–69.
Moroni G, Longhi S, Giglio E, Messa P, et al. What happens after complete withdrawal of therapy in patients with lupus nephritis. Clin Exp Rheumatol. 2013;31 (Suppl. 78):S75-S81.
Moroni G, Gallelli B, Quaglini S, et al. Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up. Nephrol Dial Transplant. 2006;21:1541–48.
Alvarado AS, Malvar A, Lococo B, et al. The value of repeat kidney biopsy in quiescent Argentinian lupus nephritis patients. Lupus. 2014;23(8):840-7.
